Attovia Therapeutics, Inc. (ATTO) SEC filings
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.13−0.68 (-4.30%)
Close on Nov 13, 2026Market cap $690.70MP/E –Yield –
SEC filings
5 of Attovia Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Sep 30, 2026 | Nov 9, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 9, 2026 | Nov 9, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 2, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 6, 2026 | Aug 6, 2026 | SEC EDGAR |
See a number that looks wrong?